InvestSMART

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

ALERT: Price-sensitive ASX Announcement for NSB
Current share price for NSB : $0.064 -0.051 (-44.35%)+
Announcement
Release
30 Oct 2025 9:10AM
Price at Release
$0.115
Full Release
download
Summary
NeuroScientific Biopharmaceuticals Ltd (NSB) provided its Quarterly Activities and Appendix 4C Cash Flow Report for the quarter ended 30 September 2025. The company reported a cash position of approximately $6.9 million. For the quarter, NSB's research and development payments amounted to $39,000, staff costs were $138,000, and administration and corporate costs were $477,000. Payments to related parties, including director fees and salaries, totaled $84,000. Notable corporate developments include the approval of initial patients under the TGA's Special Access Program for Crohn’s disease and the appointment of Nathan Smith as CEO and Dr. Catherine Cole as Chief Medical Officer. The company is focused on its proprietary StemSmart™ technology targeting Crohn's disease and the peptide-based compound EmtinB™. The report also highlights NSB's partnership with Q-Gen Cell Therapies to scale up the production of StemSmart™ for clinical trials.
Key Points
  • NeuroScientific Biopharmaceuticals reported a cash position of $6.9 million as of 30 September 2025.
  • Research and development payments for the quarter were $39,000.
  • Staff costs for the quarter were $138,000, while administration and corporate costs were $477,000.
  • Payments to related parties totaled $84,000, covering director fees and salaries.
  • NSB announced approval of initial patients under TGA's Special Access Program for Crohn’s disease.
  • Nathan Smith was appointed as CEO, and Dr. Catherine Cole as Chief Medical Officer.
  • The company is focused on StemSmart™ technology for Crohn's disease and the EmtinB™ compound.
  • NSB partnered with Q-Gen Cell Therapies for StemSmart™ clinical trial production.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.